Medicus Pharma (NASDAQ:MDCX) Raised to “Sell” at Wall Street Zen

Medicus Pharma (NASDAQ:MDCX) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Weiss Ratings raised Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $450.00.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock opened at $1.88 on Friday. The company has a market capitalization of $2.37 million, a price-to-earnings ratio of -0.02 and a beta of 0.30. The business has a fifty day simple moving average of $7.27 and a two-hundred day simple moving average of $23.43. Medicus Pharma has a 1 year low of $1.82 and a 1 year high of $127.50.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($10.50) EPS for the quarter, missing analysts’ consensus estimates of ($6.38) by ($4.12). As a group, equities analysts anticipate that Medicus Pharma will post -36.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MDCX. Interchange Capital Partners LLC increased its stake in Medicus Pharma by 33.9% in the 3rd quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock valued at $343,000 after buying an additional 538,039 shares during the last quarter. Sterling Investment Advisors Ltd. purchased a new stake in Medicus Pharma during the second quarter valued at about $45,000. Finally, Private Advisor Group LLC boosted its holdings in Medicus Pharma by 36.8% in the 1st quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after buying an additional 64,560 shares during the period.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.